SmithKline Beecham’s Dyazide
Executive Summary
1989 U.S. sales were $186 mil., up 21% for the year. The roughly $39 mil. increase in sales for Dyazide, which is off-patent, came during a year when FDA withdrew the ANDAs for all generic versions of the diuretic/antihypertensive hydrochlorothiazide. Tagamet (cimetidine) U.S. sales rose 14%, the firm said, and were up 8.5% worldwide, remaining at just over $1 bil.